Treatment of atopic dermatitis with tradipitant
The disclosure relates generally to improvements in the treatment of pruritus, atopic dermatitis (AD), and associated symptoms with tradipitant. More particularly, it relates to a method for increasing the likelihood of achieving optimal therapeutic response in the treatment of an AD patient, where the AD patient is one for whom a potential therapy of choice may include the administration of an amount of an NK-1 antagonist, e.g. tradipitant effective to treat the patient's AD.
1 . A method comprising:
selecting for treatment an individual suffering from atopic dermatitis, wherein the individual is selected for treatment by:
examining the individual in a manner sufficient to assess a severity or an extent of the atopic dermatitis;
determining that the individual suffers from atopic dermatitis of mild severity or extent; and
orally administering tradipitant to the selected individual in an amount effective to treat the atopic dermatitis.
2 . The method of claim 1 , wherein the amount of tradipitant effective to treat the atopic dermatitis is about 170 mg/day.
3 . The method of claim 2 , wherein the amount of tradipitant effective to treat the atopic dermatitis is 170 mg/day given as 85 mg twice daily (bid).
4 . The method of claim 1 , wherein the amount of tradipitant effective to treat the atopic dermatitis is 100-400 mg/day.
5 . The method of claim 4 , wherein the amount of tradipitant effective to treat the atopic dermatitis is 100-300 mg/day.
6 . The method of claim 5 , wherein the amount of tradipitant effective to treat the atopic dermatitis is 100-200 mg/day.
7 . The method of claim 4 , wherein the amount of tradipitant effective to treat the atopic dermatitis is 170-340 mg/day.
8 . The method of claim 7 , wherein the amount of tradipitant effective to treat the atopic dermatitis is 170-255 mg/day.
9 . The method of claim 1 , wherein the atopic dermatitis of mild severity or extent is characterized by an Investigator's Global Assessment (IGA) score corresponding to a score of 1 or 2 out of 4.
10 . The method of claim 1 , wherein the atopic dermatitis of mild severity or extent is characterized by a body surface area (BSA) score of 10% or less.
11 . A method of treating atopic dermatitis in an individual in need thereof, comprising:
orally administering to the individual tradipitant at a dose of 100-400 mg/day in a solid immediate release form,
wherein the individual suffers from atopic dermatitis of mild severity or extent.
12 . The method of claim 11 , wherein the atopic dermatitis of mild severity or extent is represented by an Investigator's Global Assessment (IGA) score corresponding to a score of 2 or less on a scale of 1-4.
13 . The method of claim 12 , wherein the atopic dermatitis of mild severity or extent is represented by an IGA score corresponding to a score of 1 or 2 on a scale of 1-4.
14 . The method of claim 11 , wherein the atopic dermatitis of mild severity or extent is represented by a body surface area (BSA) score of 10% or less.
15 . The method of claim 11 , wherein the dose of tradipitant comprises 100-300 mg/day.
16 . The method of claim 15 , wherein the dose of tradipitant comprises 100-200 mg/day.
17 . The method of claim 16 , wherein the dose of tradipitant comprises 170 mg/day.
18 . The method of claim 17 , wherein the dose of tradipitant comprises 170 mg/day, given as 85 mg twice daily (bid).
19 . The method of claim 11 , wherein the dose of tradipitant comprises 170-340 mg/day.
20 . The method of claim 19 , wherein the dose of tradipitant comprises 170-255 mg/day.